Russian Journal of Bioorganic Chemistry · 2021 · 15 citations · 29 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DiscoverySynthetic Medicinal ChemistryLead Compound DesignPurine AnalogsPurine AnaloguesPurine ChemistryPyrimidine AnalogsPyrimidine Analogues
Abstract In search of the best anticancer agents, a series of novel fused [1,2,3]triazolo[4',5':3,4] pyrrolo[2,1-f]purine derivatives in one vessel was synthesized using 8-bromo-1,3-dimethyl-7-(prop-2-yn-1-yl)-1H-purine-2,6(3H,7H)-dione and various arylazides. The newly synthesized derivatives were evaluated for their in vitro anti-proliferative activity against four human cancer cell lines (MCF-7, HeLa, A-549 and U-87MG). 3-(3,5-dichlorophenyl)-5,7-dimethyl-7,10-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[2,1-f]purine-6,8(3H,5H)-dione and 5,7-dimethyl-3-(4-nitrophenyl)-3,10-dihydro-[1,2,3]triazolo[4',5':3.4]pyrrolo[2,1-f]purine-6,8 (5H,7H)-dione are showed stronger activity against MCF-7 and A-549 with IC50 values ranging from 11.5 ± 0.64 to 15.3 ± 0.81 μM, which are comparable to the standard drug doxorubicin. Molecular docking studies have also been conducted to complement the experimental results.
29
Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
Jin H. Park, Yingting Liu, Mark A. Lemmon et al. · Biochemical Journal · 2012 · 403 citations · Full text
Medicine, Oncology, Pharmacology +17
Matthias Eckhardt, Elke Langkopf, Michael Mark et al. · Journal of Medicinal Chemistry · 2007 · 284 citations · Full text